author={Kunal Patel and Anthony V Aspesi and Kirk E. Evoy},
  journal={Reactions Weekly},
Objective: To review the efficacy, safety, and pharmacology data available for suvorexant and determine its role in therapy as compared with other agents available for the treatment of insomnia. Data Sources: A PubMed search using the terms suvorexant and MK-4305 (the original name given to suvorexant during early trials) was conducted in December 2014 to identify initial literature sources. No time frame was used for exclusion of older trials. Study Selection and Data Extraction: Animal… 

Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications

The role of orexin receptor antagonists in disorders of sleep/wake and other potential neuropsychiatric conditions, with a focus on suvorexant, which is currently the only approved agent in this class, is outlined.

Melatonin, Ramelteon, Suvorexant, and Dexmedetomidine to Promote Sleep and Prevent Delirium in Critically Ill Patients

Melatonin, ramelteon, suvorexant, and dexmedetomidine may promote sleep and improve a variety of patient-centric outcomes such as delirium in critically ill patients in the intensive care unit.

Complexation of Andrographolide, Mirabegron and Suvorexant and Bioactivity Study of the Complexes

The research findings that three new drug compounds were synthesized by complexation way which could be due to interaction of andrographolide and suvorexant; androg grapholides and mirabegron, and suVorexants and mirABegron.

Identification of Suvorexant in Blood Using LC-MS-MS: Important Considerations for Matrix Effects and Quantitative Interferences in Targeted Assays.

Efforts to ameliorate matrix effects in the absence of an isotopically labeled internal standard are described, which are highly variable and heavily dependent on the physico-chemical properties of the substance.

Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods

It was shown that L4 was the most potent antagonistic ligand to orexin A and displayed an IC50 of 2.2 µM, offering some promise mainly for the treatment of insomnia, while the studied compounds possess an affinity towards the OX2R.

Quantification of suvorexant in blood using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry.

  • B. SkillmanS. Kerrigan
  • Chemistry
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • 2018

Discovery of the Potential Novel Pharmacodynamic Substances From Zhi-Zi-Hou-Po Decoction Based on the Concept of Co-Decoction Reaction and Analysis Strategy

It was surprisingly found that 125 new ingredients were produced during the co-decoction, 2 of which were absorbed into the blood and 1 of which was absorbed into brain tissue, which may clarify the mechanism of action of ZZHPD in treating insomnia and depression.

PSPH-D-18-00526: Effect of a dual orexin receptor antagonist (DORA-12) on sleep and event-related oscillations in rats exposed to ethanol vapor during adolescence

It is shown that DORA-12 can affect the sleep disturbance that is associated with a history of adolescent ethanol exposure and also has several other sleep-promoting effects that are equivalent in both ethanol and control rats.

In vivo Evidence for Brain Region-Specific Molecular Interactions Between Cannabinoid and Orexin Receptors

Data show that CB1R-OX1R colocalization in the ventral striatum underlies cataleptic additivity between CP55,940 and the DORA TCS-1102, and cannabinoid-orexin receptor interactions are sex-specific with regards to brain region and functionality.

A New Positron Emission Tomography Probe for Orexin Receptors Neuroimaging

A novel PET probe ([11C]CW24) for OXRs in the brain that has high brain uptake in rodents and nonhuman primates, suitable metabolic stability, and appropriate distribution and pharmacokinetics for brain positron emission tomography (PET) imaging is reported.


Syndrome of inappropriate antidiuretic hormone secretion induced by suvorexant: a case report.

Clinicians should be aware of the possibility of SIADH induced by suvorexant, which has fewer adverse drug reactions and is considered relatively safe, after a 77-year-old man with type II diabetes was admitted to the Jichi Medical University Hospital for the treatment of major depression.